BackArmata Pharmaceuticals Overview

Armata Pharmaceuticals Total Current Liabilities

Track Armata Pharmaceuticals's total current liabilities ($250M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Total Current Liabilities
$250.20M
108.35% YoYΔ $130.11M vs prior year quarter

Peer trimmed avg / median

Loading

Armata Pharmaceuticals Total Current Liabilities History

Loading

Armata Pharmaceuticals vs. peers: Total Current Liabilities Comparison

Loading

Armata Pharmaceuticals Total Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Armata Pharmaceuticals (ARMP) FAQ

As of the most recent data (June 2026), ARMP shows a total current liabilities of $250M. That compares with $120M in the prior-year period — up 108.4% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, ARMP's total current liabilities is now $250M (was $120M) — a 108.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Armata Pharmaceuticals is outperforming or lagging.

Tracking ARMP's total current liabilities over time shows whether Armata Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $250M That compares with $120M in the prior-year period — up 108.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total current liabilities page, Stockcircle has Armata Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total current liabilities (currently $250M) with ownership activity and broader fundamentals.

Armata Pharmaceuticals's total current liabilities is $250M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.